Abstract
Although isoniazid (isonicortinic acid hydrazide, INH) is widely used for the treatment of tuberculosis, its molecular target has remained elusive. In response to INH treatment, saturated hexacosanoic acid (C26:0) accumulated on a 12-kilodalton acyl carrier protein (AcpM) that normally carried mycolic acid precursors as long as C50. A protein species purified from INH-treated Mycobacterium tuberculosis was shown to consist of a covalent complex of INH, AcpM, and a β-ketoacyl acyl carrier protein in synthase, KasA. Amino acid- altering mutations in the KasA protein were identified in INH-resistant patient isolates that lacked other mutations associated with resistance to this drug.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1607-1610 |
| Number of pages | 4 |
| Journal | Science |
| Volume | 280 |
| Issue number | 5369 |
| DOIs | |
| State | Published - Jun 5 1998 |
ASJC Scopus subject areas
- General
Fingerprint
Dive into the research topics of 'Inhibition of a Mycobacterium tuberculosis β-Ketoacyl ACP synthase by isoniazid'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS